Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP3710)
Name
Gamma linolenic acid
Synonyms
gamma-Linolenic acid; GAMOLENIC ACID; 506-26-3; (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid; (Z,Z,Z)-6,9,12-Octadecatrienoic acid; (6,9,12)-linolenic acid; CCRIS 7668; all-cis-6,9,12-Octadecatrienoic acid; gamoleic acid; Ligla; UNII-78YC2MAX4O; 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-; GLA; (6Z,9Z,12Z)-Octadecatrienoic acid; Gamma-?Linolenic acid; .gamma.-Linolenic Acid; 6Z,9Z,12Z-octadecatrienoic acid; (6Z,9Z,12Z)-6,9,12-Octadecatrienoic acid; 78YC2MAX4O; cis-Delta(6,9,12)-octadecatrienoic acid; 6(Z),9(Z),12(Z)-Octadecatrienoic acid; 6-cis,9-cis,12-cis-Octadecatrienoic acid; cis,cis,cis-6,9,12-Octadecatrienoic acid; CHEMBL464982; CHEBI:28661; MFCD00065718; 6,9,12-Octadecatrienoic acid; 6,9,12-all-cis-Octadecatrienoic acid; NCGC00160469-01; GAMMA-LINOLENIC ACID (18:3 n-6); C18:3n-6,9,12; cis-6, cis-9, cis-12-octadecatrienoic acid; 18:3 (n-6); Efamast; Epogam; Acido gamolenico; 6Z,9Z,12Z-octadecatrienoate; Acide gamolenique; Acide gamolenique [French]; Acido gamolenico [Spanish]; Acidum gamolenicum; Acidum gamolenicum [Latin]; Gamolenic acid [INN:BAN]; (6Z,9Z,12Z)-Octadecatrienoate; SMR000058609; all-cis-6,9,12-octadecatrienoate; cis-Delta(6,9,12)-octadecatrienoate; Viacutan; Gammolenic acid; gamma-Linolensaeure; Gamma-linoleic acid; gamma-linolenic-acid; gamma-Llnolenic acid; C18:3,n-6; Gamolenic acid (INN); cis-6,cis-9,cis-12-Octadecatrienoic acid; 6,9,12-Octadecatrienoate; DSSTox_CID_26170; DSSTox_RID_81401; DSSTox_GSID_46170; SCHEMBL19418; BSPBio_001338; MLS001333661; MLS001333662; Octadeca-6,9,12-triensaeure; BML3-B06; GTPL4710; DTXSID7046170; NDI 609; HMS1361C20; HMS1791C20; HMS1989C20; HMS2230A18; HMS3402C20; HMS3649H09; 6,9,12-all-cis-Octadecatrienoate; HY-N7140; ZINC3777423; Tox21_111835; BDBM50269532; LMFA01030141; s5743; C18:3, n-6,9,12 all-cis; (Z,Z,Z)-6,9,12-Octadecatrienoate; AKOS022175367; z,z,z-6,9,12-Octadecatrienoic acid; CS-W012291; DB13854; gamma-Linolenic acid, >=99%, liquid; z,z,z-octadeca-6,9,12-trienoic acid; 6(Z),9(Z),12(Z)-Octadecatrienoate; IDI1_033808; gamma-Linolenic acid, analytical standard; NCGC00160469-02; NCGC00160469-03; NCGC00160469-04; C18:3 (n-6); CAS-506-26-3; DS-10685; M520; DB-029858; L0152; Octadecatrienoic acid, 6,9,12-(Z,Z,Z)-; C06426; D07213; 506L263; Q415885; SR-01000838334; SR-01000838334-2; 18:3(N-6); BRD-K18059238-001-02-1; D58CCA4A-7FFA-4E8B-A758-EAA7D073B343; C18H30O2 (cis,cis,cis-octadeca-6,9,12-trienoic acid); UNII-116Z6MZN1M component VZCCETWTMQHEPK-QNEBEIHSSA-N; UNII-44NH37HHP9 component VZCCETWTMQHEPK-QNEBEIHSSA-N; UNII-F85N2YHE4E component VZCCETWTMQHEPK-QNEBEIHSSA-N; cis,cis,cis,6,9,12-Octa-decatrienoic acid-18:3 n6 lithium salt
    Click to Show/Hide
Species Origin Gossypium hirsutum ...     Click to Show/Hide
Gossypium hirsutum
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Malvales
Family: Malvaceae
Genus: Gossypium
Species: Gossypium hirsutum
Disease Allergic/hypersensitivity disorder [ICD-11: 4A80-4A85] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C18H30O2
PubChem CID
5280933
Canonical SMILES
CCCCCC=CCC=CCC=CCCCCC(=O)O
InChI
1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-
InChIKey
VZCCETWTMQHEPK-QNEBEIHSSA-N
CAS Number
CAS 506-26-3
ChEBI ID
CHEBI:28661
TTD Drug ID
D0UE9X
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          5-fluorouracil      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model MIA PaCa-2 CVCL_0428 Pancreatic ductal adenocarcinoma Homo sapiens
PANC-1 CVCL_0480 Pancreatic ductal adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)
GLA has a synergistic effect with gemcitabine at concentrations that correspond to in vivo therapeutic doses. GLA with 5-FU is synergistic only at a tight range of high concentrations of 5-FU. GLA lacks toxic side effects and may be useful in combination with gemcitabine.
          Vinorelbine      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model MDA-MB-231 CVCL_0062 Breast adenocarcinoma Homo sapiens
T-47D CVCL_0553 Invasive breast carcinoma Homo sapiens
SK-BR-3 CVCL_0033 Breast adenocarcinoma Homo sapiens
MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
                    Experimental
                    Result(s)
Some UFAs can be used as modulators of tumor cell chemosensitivity.
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines. Pancreatology. 2003;3(5):367-73; discussion 373-4.
Reference 3 Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res Treat. 2002 Apr;72(3):203-19.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China